Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cyrus Mehta

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
JAMA Network Open|July 12, 2022
Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional TrialsJay J H Park, Behnam Sharif, Ofir Harari, et al.
American Heart Journal|October 11, 2011
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndromeWilliam B White, George L Bakris, Richard M Bergenstal, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 DiabetesMary Jane Geiger, Cyrus Mehta, J Rick Turner, et al.
Nature Reviews. Drug Discovery|October 10, 2009
The future of drug development: advancing clinical trial designJohn Orloff, Frank Douglas, Jose Pinheiro, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 3, 2020
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final resultsBrian Olshansky, Deepak L Bhatt, Michael Miller, et al.
Journal of the American College of Cardiology|April 16, 2021
Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the WeekJames L Januzzi, John M Canty, Saumya Das, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Pain|May 29, 2014
Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendationsJennifer S Gewandter, Robert H Dworkin, Dennis C Turk, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
JAMA Network Open|July 12, 2022
Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional TrialsJay J H Park, Behnam Sharif, Ofir Harari, et al.
American Heart Journal|October 11, 2011
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndromeWilliam B White, George L Bakris, Richard M Bergenstal, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 DiabetesMary Jane Geiger, Cyrus Mehta, J Rick Turner, et al.
Nature Reviews. Drug Discovery|October 10, 2009
The future of drug development: advancing clinical trial designJohn Orloff, Frank Douglas, Jose Pinheiro, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 3, 2020
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final resultsBrian Olshansky, Deepak L Bhatt, Michael Miller, et al.
Journal of the American College of Cardiology|April 16, 2021
Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the WeekJames L Januzzi, John M Canty, Saumya Das, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Pain|May 29, 2014
Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendationsJennifer S Gewandter, Robert H Dworkin, Dennis C Turk, et al.
Pageof 4